Financial experts at Macquarie have lowered their price target on Australian biotech company, CSL (ASX:CSL) to A$321 per share, a drop from the previous figure of A$326 per share.

Currently, CSL’s shares have seen a decline of 0.3 percent.

One of the main pipeline products for CSL is CSL112, a plasma-derived apolipoprotein A-I, which looks to prevent major cardiovascular events.

Regardless of the lowered price target, Macquarie has maintained their ‘Outperform’ rating on CSL.

The price target was reduced due to marginally increased risk-weighted contributions coming from CSL112.

CSL’s shares have seen a significant drop this year, with a decrease of 13.6 percent noted at the last close.

CSL is a leading biotech company that specializes in the development of innovative therapies centered around human health.